AR049696A1 - Derivados de indol - Google Patents
Derivados de indolInfo
- Publication number
- AR049696A1 AR049696A1 ARP050102510A ARP050102510A AR049696A1 AR 049696 A1 AR049696 A1 AR 049696A1 AR P050102510 A ARP050102510 A AR P050102510A AR P050102510 A ARP050102510 A AR P050102510A AR 049696 A1 AR049696 A1 AR 049696A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- hydroxyalkyl
- lower alkyl
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 18
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000004686 alkyl sulfanyl alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 1
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000011737 fluorine Chemical group 0.000 abstract 1
- 229910052731 fluorine Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Procesos y composiciones farmacéuticas y usos. Los compuestos son utiles para el tratamiento y/o prevencion de enfermedades asociadas con la modulacion de receptores H3. Reivindicacion 1: Compuestos de la formula general (1), en la que: X es O o S; R1 se selecciona entre el grupo formado por hidrogeno; alquilo inferior, alquenilo inferior, alquinilo inferior; cicloalquilo cicloalquilalquilo inferior; hidroxialquilo inferior; alcoxialquilo inferior; alquilsulfanilalquilo inferior; dialquilaminoalquilo inferior; dialquilcarbamoilalquilo inferior; fenilo sin sustituir o sustituido con uno o dos grupos seleccionados con independencia entre sí entre alquilo inferior, halogenoalcoxi inferior o hidroxialquilo inferior; fenilalquilo inferior en el que el anillo fenilo puede estar sin sustituir o sustituido con uno o dos grupos seleccionados con independencia entre sí entre alquilo inferior, halogeno, alcoxi inferior o hidroxialquilo inferior; heteroarilalquilo inferior en el que el anillo heteroarilo puede estar sin sustituir o sustituido con uno o dos grupos seleccionados con independencia ente sí entre alquilo inferior, halogeno, alcoxi inferior o hidroxialquilo inferior; y heterociclilalquilo inferior en el que el anillo heterociclilo puede estar sin sustituir o sustituido con uno o dos grupos alquilo inferior; R2 se selecciona entre el grupo formado por hidrogeno; alquilo inferior, alquenilo inferior, alquinilo inferior; cicloalquilo cicloalquilalquilo inferior; hidroxialquilo inferior; alcoxialquilo inferior; alquilsulfanilalquilo inferior; dialquilaminoalquilo inferior; dialquilcarbamoilalquilo inferior; fenilo sin sustituir o sustituido con uno o dos grupos seleccionados con independencia entre sí entre alquilo inferior, halogenoalcoxi inferior o hidroxialquilo inferior; fenilalquilo inferior en el que el anillo fenilo puede estar sin sustituir o sustituido con uno o dos grupos seleccionados con independencia entre sí entre alquilo inferior, halogeno, alcoxi inferior o hidroxialquilo inferior; heteroarilalquilo inferior en el que el anillo heteroarilo puede estar sin sustituir o sustituido con uno o dos grupos seleccionados con independencia ente sí entre alquilo inferior, halogeno, alcoxi inferior e hidroxialquilo inferior; y heterociclilalquilo inferior en el que el anillo heterociclilo puede estar sin sustituir o sustituido con uno o dos grupos alquilo inferior; o R1 y R2 junto con el átomo de nitrogeno al que están unidos forman un anillo heterocíclico de 4, 5, 6 o 7 eslabones, saturado o parcialmente insaturado que contiene opcionalmente otro heteroátomo elegido entre nitrogeno, oxígeno o azufre; dicho anillo heterocíclico saturado está sin sustituir o sustituido con uno, dos o tres grupos seleccionados con independencia entre sí entre alquilo inferior, halogeno, halogenoalquilo, hidroxi, hidroxialquilo inferior, alcoxi inferior, oxo, fenilo, bencilo, piridilo y carbamoilo; o está condensado con un anillo fenilo, dicho anillo fenilo está sin sustituir o sustituido con uno, dos o tres grupos seleccionados con independencia entre sí entre alquilo inferior, alcoxi inferior y halogeno; R3 se selecciona entre el grupo formado por hidrogeno, alquilo inferior, alcoxialquilo inferior, halogenoalquilo inferior, cicloalquilalquilo inferior, alquilsulfonilo inferior y alcanoilo inferior; R4 es -O-Het y R5 es hidrogeno; o R4 es hidrogeno o fluor y R5 es -O-Het; Het se selecciona entre un resto de grupo de formulas (2), en la que: m es 0, 1 o 2; R6 se selecciona entre alquilo inferior, cicloalquilo, cicloalquilalquilo inferior y fenilalquilo inferior; n es 0, 1 o 2; R7 es alquilo inferior; p es 0, 1 o 2; q es 0, 1 o 2; X se selecciona entre CR10R10', O y S; R8, R8', R9, R9', R10, R10', R11 y R11' con independencia entre sí se seleccionan entre el grupo formado por hidrogeno, alquilo inferior, hidroxi, halogeno y dialquilamino; o R9 y R10 juntos forman un doble enlace; R12 es alquilo inferior; R13 es alquilo C3-6; y sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04102839 | 2004-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049696A1 true AR049696A1 (es) | 2006-08-30 |
Family
ID=34982342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102510A AR049696A1 (es) | 2004-06-21 | 2005-06-17 | Derivados de indol |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7361682B2 (es) |
| EP (1) | EP1761519B1 (es) |
| JP (1) | JP4652404B2 (es) |
| CN (1) | CN1972926B (es) |
| AR (1) | AR049696A1 (es) |
| AT (1) | ATE394391T1 (es) |
| AU (1) | AU2005254658B2 (es) |
| BR (1) | BRPI0512335A (es) |
| CA (1) | CA2569611C (es) |
| DE (1) | DE602005006567D1 (es) |
| DK (1) | DK1761519T3 (es) |
| ES (1) | ES2306170T3 (es) |
| IL (1) | IL179737A (es) |
| MX (1) | MXPA06014810A (es) |
| MY (1) | MY139941A (es) |
| NO (1) | NO20070336L (es) |
| NZ (1) | NZ551663A (es) |
| PL (1) | PL1761519T3 (es) |
| PT (1) | PT1761519E (es) |
| RU (1) | RU2382778C2 (es) |
| TW (1) | TW200612936A (es) |
| WO (1) | WO2005123716A1 (es) |
| ZA (1) | ZA200610416B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1841734B1 (en) * | 2005-01-19 | 2009-07-29 | F. Hoffmann-Roche AG | 5-aminoindole derivatives |
| BRPI0619266A2 (pt) * | 2005-11-30 | 2011-09-27 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, obesidade, diabetes do tipo ii e seu uso |
| CA2630270A1 (en) * | 2005-11-30 | 2007-06-07 | F. Hoffmann-La Roche Ag | 5-substituted indole-2-carboxamide derivatives |
| KR101124156B1 (ko) | 2005-11-30 | 2012-03-23 | 에프. 호프만-라 로슈 아게 | 1,5-치환된 인돌-2-일 아마이드 유도체 |
| WO2007115938A1 (en) * | 2006-04-12 | 2007-10-18 | F. Hoffmann-La Roche Ag | 5-amido-2-carboxamide indoles |
| US7432255B2 (en) * | 2006-05-16 | 2008-10-07 | Hoffmann-La Roche Inc. | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives |
| US7514433B2 (en) * | 2006-08-03 | 2009-04-07 | Hoffmann-La Roche Inc. | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives |
| PT2354124E (pt) | 2006-12-19 | 2013-04-09 | Hoffmann La Roche | Derivados de heteroaril-pirrolidinilo e piperidinil-cetona |
| EP2079694B1 (en) | 2006-12-28 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| US7648979B2 (en) * | 2007-02-07 | 2010-01-19 | Hoffmann-La Roche Inc. | 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives |
| US7507736B2 (en) | 2007-02-07 | 2009-03-24 | Hoffmann-La Roche Inc. | Indol-2-yl-piperazin-1-yl-methanone derivatives |
| US7557108B2 (en) * | 2007-02-07 | 2009-07-07 | Hoffmann-La Roche Inc. | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones |
| WO2008109333A1 (en) * | 2007-03-01 | 2008-09-12 | Janssen Pharmaceutica N.V. | Indole and benzothiophene compounds as modulators of the histamine h3 receptor |
| CN101796043A (zh) * | 2007-07-25 | 2010-08-04 | 霍夫曼-拉罗奇有限公司 | 苯并呋喃-和苯并[b]噻吩-2-羧酸酰胺衍生物及其作为阻胺3受体调节剂的应用 |
| HRP20120837T1 (hr) * | 2007-08-31 | 2012-11-30 | Astellas Pharma Inc. | Derivati piperidina |
| MX2010005298A (es) * | 2007-11-16 | 2010-06-30 | Rigel Pharmaceuticals Inc | Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos. |
| EP2231666B1 (en) | 2007-12-12 | 2015-07-29 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| CN112079769A (zh) | 2008-04-23 | 2020-12-15 | 里格尔药品股份有限公司 | 用于治疗代谢障碍的甲酰胺化合物 |
| US20100035862A1 (en) * | 2008-06-25 | 2010-02-11 | Abbott Laboratories | Novel aza-cyclic indole-2-carboxamides and methods of use thereof |
| FR2950053B1 (fr) * | 2009-09-11 | 2014-08-01 | Fournier Lab Sa | Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson |
| AU2012388383C1 (en) * | 2012-08-23 | 2016-03-17 | Suven Life Sciences Limited | Acrylamide compounds as Histamine H3 receptor ligands |
| EP2722329A1 (en) * | 2012-10-18 | 2014-04-23 | F. Hoffmann-La Roche AG | Indol-amide compounds as beta-amyloid inhbitors |
| KR101551313B1 (ko) * | 2014-07-28 | 2015-09-09 | 충남대학교산학협력단 | 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물 |
| CN106065008B (zh) * | 2016-06-16 | 2018-06-05 | 黑龙江中医药大学 | 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用 |
| JP7316216B2 (ja) * | 2017-02-17 | 2023-07-27 | トレベナ・インコーポレイテッド | ５員アザ複素環を含有するデルタ－オピオイド受容体調節化合物、その使用方法及び製造方法 |
| CA3052479A1 (en) | 2017-02-17 | 2018-08-23 | Trevena, Inc. | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2705095B1 (fr) * | 1993-05-12 | 1995-06-23 | Adir | Nouveaux indoles substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| KR100608472B1 (ko) * | 1997-12-24 | 2006-08-09 | 사노피-아벤티스 도이칠란트 게엠베하 | 인자 Ｘａ의 억제제로서의 인돌 유도체 및 이를 함유하는 약제학적 조성물 |
| EP0978512A1 (en) * | 1998-07-29 | 2000-02-09 | Societe Civile Bioprojet | Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications |
| DE60138605D1 (de) * | 2000-03-31 | 2009-06-18 | Ortho Mcneil Pharm Inc | Phenyl-substituierte indole als h3 histaminrezeptorantagonisten |
| HU227197B1 (en) * | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| US6803362B2 (en) * | 2001-03-09 | 2004-10-12 | Ortho-Mcneil Pharmaceutical Inc. | Heterocyclic compounds |
| US6673829B2 (en) * | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
| PT1539742E (pt) * | 2002-06-24 | 2007-01-31 | Schering Corp | Derivados de índole úteis como antagonistas h3 de histamina |
-
2005
- 2005-06-13 NZ NZ551663A patent/NZ551663A/en unknown
- 2005-06-13 PT PT05756581T patent/PT1761519E/pt unknown
- 2005-06-13 JP JP2007517135A patent/JP4652404B2/ja not_active Expired - Fee Related
- 2005-06-13 AT AT05756581T patent/ATE394391T1/de active
- 2005-06-13 WO PCT/EP2005/006303 patent/WO2005123716A1/en not_active Ceased
- 2005-06-13 PL PL05756581T patent/PL1761519T3/pl unknown
- 2005-06-13 DK DK05756581T patent/DK1761519T3/da active
- 2005-06-13 MX MXPA06014810A patent/MXPA06014810A/es active IP Right Grant
- 2005-06-13 ES ES05756581T patent/ES2306170T3/es not_active Expired - Lifetime
- 2005-06-13 AU AU2005254658A patent/AU2005254658B2/en not_active Ceased
- 2005-06-13 CA CA2569611A patent/CA2569611C/en not_active Expired - Fee Related
- 2005-06-13 CN CN2005800204455A patent/CN1972926B/zh not_active Expired - Fee Related
- 2005-06-13 BR BRPI0512335-6A patent/BRPI0512335A/pt not_active IP Right Cessation
- 2005-06-13 RU RU2007102224/04A patent/RU2382778C2/ru not_active IP Right Cessation
- 2005-06-13 EP EP05756581A patent/EP1761519B1/en not_active Expired - Lifetime
- 2005-06-13 DE DE602005006567T patent/DE602005006567D1/de not_active Expired - Lifetime
- 2005-06-17 AR ARP050102510A patent/AR049696A1/es not_active Application Discontinuation
- 2005-06-20 TW TW094120464A patent/TW200612936A/zh unknown
- 2005-06-20 MY MYPI20052800A patent/MY139941A/en unknown
- 2005-06-20 US US11/157,093 patent/US7361682B2/en not_active Expired - Fee Related
-
2006
- 2006-11-30 IL IL179737A patent/IL179737A/en not_active IP Right Cessation
- 2006-12-12 ZA ZA200610416A patent/ZA200610416B/xx unknown
-
2007
- 2007-01-18 NO NO20070336A patent/NO20070336L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008503511A (ja) | 2008-02-07 |
| DK1761519T3 (da) | 2008-07-21 |
| DE602005006567D1 (de) | 2008-06-19 |
| ZA200610416B (en) | 2008-09-25 |
| US20050282864A1 (en) | 2005-12-22 |
| EP1761519B1 (en) | 2008-05-07 |
| BRPI0512335A (pt) | 2008-03-04 |
| US7361682B2 (en) | 2008-04-22 |
| ES2306170T3 (es) | 2008-11-01 |
| AU2005254658A1 (en) | 2005-12-29 |
| MXPA06014810A (es) | 2007-02-12 |
| CN1972926B (zh) | 2011-02-16 |
| RU2382778C2 (ru) | 2010-02-27 |
| CN1972926A (zh) | 2007-05-30 |
| ATE394391T1 (de) | 2008-05-15 |
| NZ551663A (en) | 2009-09-25 |
| CA2569611A1 (en) | 2005-12-29 |
| IL179737A0 (en) | 2007-05-15 |
| PT1761519E (pt) | 2008-07-02 |
| MY139941A (en) | 2009-11-30 |
| EP1761519A1 (en) | 2007-03-14 |
| NO20070336L (no) | 2007-02-13 |
| IL179737A (en) | 2011-12-29 |
| WO2005123716A1 (en) | 2005-12-29 |
| RU2007102224A (ru) | 2008-07-27 |
| CA2569611C (en) | 2012-12-11 |
| TW200612936A (en) | 2006-05-01 |
| PL1761519T3 (pl) | 2008-09-30 |
| AU2005254658B2 (en) | 2011-06-16 |
| JP4652404B2 (ja) | 2011-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049696A1 (es) | Derivados de indol | |
| AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
| AR060593A1 (es) | 5-amido-2-carboxiamida-indoles | |
| AR061486A1 (es) | Derivados de 2-pirazinacarboxamida | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| PE20090441A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA | |
| ECSP045368A (es) | "antagonistas de los receptores de trombina" | |
| PE20081152A1 (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 | |
| AR058984A1 (es) | Derivados de ciclohexil piperazinil metanona | |
| AR059094A1 (es) | Derivados de ciclohexil - sulfonamida | |
| PE20090773A1 (es) | Derivados de morfolina pirimidina | |
| PE20091621A1 (es) | Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen | |
| PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
| CO5570668A2 (es) | Derivados triciclicos sustituidos de himbacina que son antagonistas del receptor de trombina y composiciones farmaceuticas que los contienen | |
| NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| AR068061A1 (es) | Derivados de bisamida biciclicos utiles como pesticidas | |
| AR045762A1 (es) | Derivados de quinazolina | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR038249A1 (es) | Compuestos derivados de quinolina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos derivados en la preparacion de un medicamento | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| AR051638A1 (es) | Compuestos de piperidinilo y su uso para tratar desordenes de respuesta al bloqueo de los canales de calcio tipo n | |
| PE20091524A1 (es) | Derivados de 2-aminopirimidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |